General Information of the Protein
Protein ID
PT02949
Protein Name
Advanced glycosylation end product-specific receptor
Secondarily
Protein Name
Receptor for advanced glycosylation end products
Gene Name
AGER
Secondarily
Gene Name
RAGE
Sequence
MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGVILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Unclassified protein
Function
Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, phospholipids and glycosaminoglycans (PubMed:27572515, PubMed:28515150, PubMed:34743181). Advanced glycosylation end products are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes (PubMed:21565706). These ligands accumulate at inflammatory sites during the pathogenesis of various diseases, including diabetes, vascular complications, neurodegenerative disorders, and cancers and RAGE transduces their binding into pro-inflammatory responses. Upon ligand binding, uses TIRAP and MYD88 as adapters to transduce the signal ultimately leading to the induction or inflammatory cytokines IL6, IL8 and TNFalpha through activation of NF-kappa-B (PubMed:21829704). Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key pro-inflammatory mediators (PubMed:19386136). Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons (PubMed:19906677). ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Participates in endothelial albumin transcytosis together with HMGB1 through the RAGE/SRC/Caveolin-1 pathway, leading to endothelial hyperpermeability (PubMed:27572515). Mediates the loading of HMGB1 in extracellular vesicles (EVs) that shuttle HMGB1 to hepatocytes by transferrin-mediated endocytosis and subsequently promote hepatocyte pyroptosis by activating the NLRP3 inflammasome (PubMed:34743181). Promotes also extracellular hypomethylated DNA (CpG DNA) uptake by cells via the endosomal route to activate inflammatory responses (PubMed:24081950, PubMed:28515150).
    Show/Hide
Uniprot ID
Primary ID:
Q15109

Secondarily ID:
A2BFI7
A6NKF0
A7Y2U9
B0V176
Q15279
Q3L1R4
Q3L1R5
Q3L1R6
Q3L1R7
Q3L1R8
Q3L1S0
Q86SN1
Q9H2X7
Q9Y3R3
V5R6A3
    Show/Hide
Ensembl ID
ENSG00000204305
HGNC ID
HGNC:320
Subcellular Location
Cell membrane
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000011 , CHO
Compound ID Compound Name Compound Formula
CP0548796
N-benzyl-4-chloro-N-cyclohexylbenzamide
   Show/Hide
C20H22ClNO
 1
1
Ki = 25 nM
   TI
   LI
   LO
   TS
Clinical Information about the Protein
Target 1 ( Advanced glycosylation end product receptor (AGER) )
Target Type Clinical trial Target
Disease 2 Target-related Diseases  2
1 Dementia [ICD-11: 6D80-6D86]
2 Diabetic nephropathy [ICD-11: GB61.Z]
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 PF-4494700 Phase 3
Dementia
2 Pyridoxamine Phase 3
Diabetic nephropathy
Target 2 ( Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA) )
Target Type Clinical trial Target